JP2021517132A5 - - Google Patents
Info
- Publication number
- JP2021517132A5 JP2021517132A5 JP2020546962A JP2020546962A JP2021517132A5 JP 2021517132 A5 JP2021517132 A5 JP 2021517132A5 JP 2020546962 A JP2020546962 A JP 2020546962A JP 2020546962 A JP2020546962 A JP 2020546962A JP 2021517132 A5 JP2021517132 A5 JP 2021517132A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- virus
- alkyl
- different
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023176993A JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639725P | 2018-03-07 | 2018-03-07 | |
| US62/639,725 | 2018-03-07 | ||
| PCT/US2019/021168 WO2019173602A1 (en) | 2018-03-07 | 2019-03-07 | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176993A Division JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517132A JP2021517132A (ja) | 2021-07-15 |
| JP2021517132A5 true JP2021517132A5 (enExample) | 2022-03-14 |
| JP7371931B2 JP7371931B2 (ja) | 2023-10-31 |
Family
ID=67846796
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546962A Active JP7371931B2 (ja) | 2018-03-07 | 2019-03-07 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2023176993A Active JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A Pending JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176993A Active JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A Pending JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210308168A1 (enExample) |
| EP (1) | EP3762372A4 (enExample) |
| JP (3) | JP7371931B2 (enExample) |
| KR (2) | KR20200140274A (enExample) |
| CN (2) | CN119633010A (enExample) |
| AU (2) | AU2019231725B2 (enExample) |
| BR (1) | BR112020018209A2 (enExample) |
| CA (1) | CA3093222A1 (enExample) |
| EA (1) | EA202092117A1 (enExample) |
| GB (2) | GB2589205B (enExample) |
| IL (1) | IL277160B2 (enExample) |
| PH (1) | PH12020551404A1 (enExample) |
| SG (1) | SG11202008527WA (enExample) |
| WO (1) | WO2019173602A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| JP2022551477A (ja) * | 2019-10-08 | 2022-12-09 | エモリー ユニバーシティー | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| CA3176661A1 (en) * | 2020-04-24 | 2021-10-28 | Memorial Sloan-Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| EP4203970A4 (en) * | 2020-08-27 | 2025-03-26 | Emory University | NEW FORMS OF ANTIVIRAL NUCLEOSIDES |
| CN114644666B (zh) * | 2020-12-18 | 2026-03-03 | 上海特化医药科技有限公司 | 5’-核苷前药的制备方法及中间体 |
| US20240092818A1 (en) * | 2020-12-18 | 2024-03-21 | Merck Sharp & Dohme Llc | Synthesis of antiviral nucleosides |
| CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
| CN112778387A (zh) * | 2021-01-15 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种Molnupiravir晶型A及其制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022174179A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| KR20240006536A (ko) * | 2021-04-09 | 2024-01-15 | 에모리 유니버시티 | 항바이러스제로서의 티오뉴클레오시드 |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| US11407779B1 (en) * | 2021-04-23 | 2022-08-09 | Divi's Laboratories Ltd. | Process for the preparation of molnupiravir |
| CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
| EP4333859A4 (en) * | 2021-05-05 | 2025-03-26 | Emory University | THERAPEUTIC COMPOSITIONS CONTAINING NUCLEOTIDES AND NUCLEOSIDES, COMBINATIONS AND USES THEREOF |
| CN113278040B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | 5’-异丁酰基-n4-羟基胞苷的制备方法 |
| WO2022262845A1 (en) * | 2021-06-18 | 2022-12-22 | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | Ester derivatives of n4-hydroxycytidine and use thereof |
| WO2023012329A1 (en) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Method of treating veterinary viral diseases |
| US20250011789A1 (en) | 2021-09-08 | 2025-01-09 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| CN113880902A (zh) * | 2021-10-26 | 2022-01-04 | 江苏睿实生物科技有限公司 | 一种Molnupiravir药物中间体及其制备方法 |
| US11541071B1 (en) * | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN114478658A (zh) * | 2022-02-22 | 2022-05-13 | 苏州正济药业有限公司 | 一种莫那比拉韦的合成方法 |
| US20250282812A1 (en) * | 2022-04-20 | 2025-09-11 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Antiviral nucleoside analogue, and pharmaceutical composition and use thereof |
| WO2024129985A2 (en) * | 2022-12-14 | 2024-06-20 | Lakewood Amedex, Inc. | Antiviral compounds, compositions, and uses thereof |
| KR20250127754A (ko) | 2022-12-23 | 2025-08-26 | 메이지 세이카 파루마 가부시키가이샤 | 에버멕틴 유도체 |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| AU2024231381A1 (en) | 2023-03-07 | 2025-09-18 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (siNA) molecules and uses thereof |
| CN121773092A (zh) * | 2023-05-05 | 2026-03-31 | 埃默里大学 | 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
| CN117567310A (zh) * | 2023-11-28 | 2024-02-20 | 重庆智合生物医药有限公司 | 一种神经酰胺np1的合成方法 |
| WO2025144872A2 (en) * | 2023-12-29 | 2025-07-03 | Adarx Pharmaceuticals, Inc. | Nucleoside-derived lipids for drug delivery |
| WO2026011167A1 (en) * | 2024-07-05 | 2026-01-08 | Emory University | Thionucleosides as antiviral agents |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4207363A1 (de) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
| JPWO2004024185A1 (ja) * | 2002-09-11 | 2006-01-26 | 道男 石橋 | 医薬または化粧料 |
| CA2664156A1 (en) * | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
| WO2009058800A2 (en) * | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
| EP2342616A2 (en) * | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| UA111761C2 (uk) * | 2011-12-20 | 2016-06-10 | Рібосаєнс Ллс | 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c |
| AP3913A (en) * | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
| EP2935304A1 (en) * | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| GEP201706757B (en) * | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| EP2981542B1 (en) * | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| MA46490A1 (fr) * | 2013-05-16 | 2021-04-30 | Riboscience Llc | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués |
| HK1224229A1 (zh) * | 2013-06-26 | 2017-08-18 | Alios Biopharma, Inc. | 取代的核苷，核苷酸及其类似物 |
| WO2015051169A2 (en) * | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP6562908B2 (ja) * | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| TN2016000566A1 (en) * | 2014-06-24 | 2018-04-04 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| HUE051986T2 (hu) * | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
| MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| WO2016134056A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| WO2016134054A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| WO2017024310A1 (en) * | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| WO2017040896A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040895A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040892A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| US11963972B2 (en) * | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
| EP3471738A4 (en) * | 2016-06-20 | 2020-01-01 | Merck Sharp & Dohme Corp. | CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES |
-
2019
- 2019-03-07 IL IL277160A patent/IL277160B2/en unknown
- 2019-03-07 SG SG11202008527WA patent/SG11202008527WA/en unknown
- 2019-03-07 CA CA3093222A patent/CA3093222A1/en active Pending
- 2019-03-07 EA EA202092117A patent/EA202092117A1/ru unknown
- 2019-03-07 JP JP2020546962A patent/JP7371931B2/ja active Active
- 2019-03-07 CN CN202411351705.8A patent/CN119633010A/zh active Pending
- 2019-03-07 GB GB2015827.5A patent/GB2589205B/en active Active
- 2019-03-07 WO PCT/US2019/021168 patent/WO2019173602A1/en not_active Ceased
- 2019-03-07 KR KR1020207028655A patent/KR20200140274A/ko not_active Ceased
- 2019-03-07 US US16/979,108 patent/US20210308168A1/en not_active Abandoned
- 2019-03-07 KR KR1020267004999A patent/KR20260028884A/ko active Pending
- 2019-03-07 CN CN201980030574.4A patent/CN112074506B/zh active Active
- 2019-03-07 BR BR112020018209-5A patent/BR112020018209A2/pt active Search and Examination
- 2019-03-07 GB GB2218405.5A patent/GB2611644B/en active Active
- 2019-03-07 EP EP19764729.0A patent/EP3762372A4/en active Pending
- 2019-03-07 AU AU2019231725A patent/AU2019231725B2/en active Active
-
2020
- 2020-09-07 PH PH12020551404A patent/PH12020551404A1/en unknown
-
2023
- 2023-07-26 US US18/359,435 patent/US20240180948A1/en active Pending
- 2023-10-12 JP JP2023176993A patent/JP7786743B2/ja active Active
-
2024
- 2024-09-19 AU AU2024219862A patent/AU2024219862A1/en active Pending
-
2025
- 2025-11-27 JP JP2025207111A patent/JP2026062641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2589205A (en) | 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto | |
| ES2380887T3 (es) | Formulaciones farmacéuticas de inhibidores de la HDAC | |
| ES2395101T3 (es) | Medicamentos antivirales para tratamiento de infecciones por arenavirus | |
| CN108135964B (zh) | 谷胱甘肽制剂和使用方法 | |
| CY1124720T1 (el) | Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων | |
| ES2656901T3 (es) | Una formulación estabilizada de pemetrexed | |
| CY1111934T1 (el) | Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη | |
| JP2008522981A5 (enExample) | ||
| HRP20180220T1 (hr) | Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija | |
| HRP20220278T1 (hr) | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima | |
| JP2011051993A5 (enExample) | ||
| JP2008518950A5 (enExample) | ||
| JP2016504284A5 (enExample) | ||
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR064370A1 (es) | Nitroderivados de bencenosulfonamidas sustituidas como inhibidores de anhidrasa carbonica composiciones farmaceuticas que los comprenden kits farmaceuticos para su administracion y su uso en la preparacion de un medicamento para el tratamiento del cancer y de trastornos oculares | |
| EP2307056A2 (en) | Stabilized aqueous formulation containing paracetamol | |
| AR054188A1 (es) | Aminas ciclicas con actividad inhibitoria del factor de coagulacion xa, metodos para su sintesis, intermediarios del proceso de obtencion de las mismas y su elaboracion, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del a | |
| JP2023540149A (ja) | 抗ウイルス化合物の製剤 | |
| BR112012029212A2 (pt) | formulação de paracetamol injetável pronta para o uso estável | |
| MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
| JP2013536257A5 (enExample) | ||
| AR065297A1 (es) | Formulaciones biodisponibles de compuestos heterociclicos | |
| CN106589346B (zh) | 水溶性聚乙二醇化氯硝柳胺及其制备方法和在抗肿瘤治疗中的应用 | |
| JP2017509701A5 (enExample) | ||
| EP3471732A1 (en) | Liposomes for the treatment of viral infections |